Base de dados : MEDLINE
Pesquisa : D03.383.931.135 [Categoria DeCS]
Referências encontradas : 431 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 44 ir para página                         

  1 / 431 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25363752
[Au] Autor:Gidwani B; Vyas A
[Ad] Endereço:a University Institute of Pharmacy, Pt. Ravi Shankar Shukla University , Raipur , Chhattisgarh , India.
[Ti] Título:Preparation, characterization, and optimization of altretamine-loaded solid lipid nanoparticles using Box-Behnken design and response surface methodology.
[So] Source:Artif Cells Nanomed Biotechnol;44(2):571-80, 2016.
[Is] ISSN:2169-141X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The objective of the present study was to prepare solid lipid nanoparticles (SLNs) of altretamine (ALT) by the hot homogenization and ultrasonication method. The study was conducted using the Box-Behnken design (BBD), with a 3(3) design and a total of 17 experimental runs, performed in combination with response surface methodology (RSM). The SLNs were evaluated for mean particle size, entrapment efficiency, and drug-loading. The optimized formulation, with a desirability factor of 0.92, was selected and characterized. In vitro release studies showed a biphasic release pattern from the SLNs for up to 24 h. The results of % EE (93.21 ± 1.5), %DL (1.15 ± 0.6), and mean diameter of (100.6 ± 2.1) nm, were very close to the predicted values.
[Mh] Termos MeSH primário: Altretamine/química
Portadores de Fármacos/química
Lipídeos/química
Nanopartículas/química
[Mh] Termos MeSH secundário: Liberação Controlada de Fármacos
Estabilidade de Medicamentos
Tamanho da Partícula
Tensoativos/química
Ondas Ultrassônicas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Drug Carriers); 0 (Lipids); 0 (Surface-Active Agents); Q8BIH59O7H (Altretamine)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141104
[St] Status:MEDLINE
[do] DOI:10.3109/21691401.2014.971462


  2 / 431 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20196698
[Au] Autor:Sun J; Deng Y; Wang S; Cao J; Gao X; Dong X
[Ad] Endereço:Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, PR China.
[Ti] Título:Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation.
[So] Source:Drug Deliv;17(3):164-70, 2010 Apr.
[Is] ISSN:1521-0464
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Liposomes incorporating sodium deoxycholate (NaDC) were prepared by the method of reverse phase evaporation and used for drug delivery by the oral route. Hexamethylmelamine (HMM), an anti-tumor agent, was chosen as a model drug and encapsulated into liposomes incorporating NaDC (NaDC-Lip). Several properties of NaDC-Lip containing HMM (HMM NaDC-Lip), such as particle size, entrapment efficiency, pinacyanol chloride (PIN) spectral characteristics with various molar ratio of NaDC/PC, as well as the vesicle stability measurements with calcein were evaluated. In vivo, the area under the plasma concentration-time curve obtained from the pharmacokinetics study of HMM NaDC-Lip was found to be approximately 9.76- and 1.21-fold higher than that of HMM solution and HMM Lip, respectively, indicating that NaDC-Lip can be used as a potential carrier for oral drug administration.
[Mh] Termos MeSH primário: Altretamine/administração & dosagem
Antineoplásicos Alquilantes/administração & dosagem
Ácido Desoxicólico/química
Lipossomos/química
[Mh] Termos MeSH secundário: Administração Oral
Altretamine/farmacocinética
Animais
Antineoplásicos Alquilantes/farmacocinética
Carbocianinas/química
Colesterol/química
Cromatografia Líquida de Alta Pressão
Portadores de Fármacos
Composição de Medicamentos
Estabilidade de Medicamentos
Feminino
Fluoresceínas/química
Lipídeos/química
Tamanho da Partícula
Ratos
Ratos Wistar
Espectrofotometria Ultravioleta
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 0 (Carbocyanines); 0 (Drug Carriers); 0 (Fluoresceins); 0 (Lipids); 0 (Liposomes); 005990WHZZ (Deoxycholic Acid); 91SZ6DGY86 (quinaldine blue); 97C5T2UQ7J (Cholesterol); Q8BIH59O7H (Altretamine); V0YM2B16TS (fluorexon)
[Em] Mês de entrada:1006
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100304
[St] Status:MEDLINE
[do] DOI:10.3109/10717541003667764


  3 / 431 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:19654952
[Au] Autor:Kwon YS; Nam JH; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
[Ad] Endereço:Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.
[Ti] Título:Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.
[So] Source:J Korean Med Sci;24(4):679-83, 2009 Aug.
[Is] ISSN:1598-6357
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between January 1997 and November 2006 and in documented clinical complete response from advanced ovarian cancer following front-line platinum-based therapy were retrospectively analyzed. The patients treated with HMM were compared to the patients of matched counterpart without consolidation therapy. Of 102 patients enrolled, 49 were treated with HMM and 53 received no consolidation treatment. For patients with HMM and observed patients, the mean age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free survival were 38 months and 21 months for patients with HMM and observed patients (P=0.235). No treatment-related adverse events were reported during the follow-up period. Although this study failed to show the significant survival benefit of consolidation therapy with HMM in patients with advanced EOC, we consider that our study can contribute data to investigate the effectiveness of consolidation therapy in epithelial ovarian cancer.
[Mh] Termos MeSH primário: Altretamine/uso terapêutico
Antineoplásicos Alquilantes/uso terapêutico
Neoplasias Epiteliais e Glandulares/tratamento farmacológico
Neoplasias Ovarianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Intervalo Livre de Doença
Feminino
Seres Humanos
Meia-Idade
Estadiamento de Neoplasias
Neoplasias Epiteliais e Glandulares/mortalidade
Neoplasias Ovarianas/mortalidade
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); Q8BIH59O7H (Altretamine)
[Em] Mês de entrada:0911
[Cu] Atualização por classe:141207
[Lr] Data última revisão:
141207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090806
[St] Status:MEDLINE
[do] DOI:10.3346/jkms.2009.24.4.679


  4 / 431 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:18811611
[Au] Autor:Samper-Ternent R; Al Snih S; Raji MA; Markides KS; Ottenbacher KJ
[Ad] Endereço:Division of Rehabilitation Sciences, University of Texas Medical Branch, Galveston, Texas 77555, USA. soalsnih@utmb.edu
[Ti] Título:Relationship between frailty and cognitive decline in older Mexican Americans.
[So] Source:J Am Geriatr Soc;56(10):1845-52, 2008 Oct.
[Is] ISSN:1532-5415
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To examine the association between frailty status and change in cognitive function over time in older Mexican Americans. DESIGN: Data used were from the Hispanic Established Population for the Epidemiological Study of the Elderly. SETTING: Five southwestern states: Texas, New Mexico, Colorado, Arizona, and California. PARTICIPANTS: One thousand three hundred seventy noninstitutionalized Mexican-American men and women aged 65 and older with a Mini-Mental State Examination (MMSE) score of 21 or higher at baseline (1995/96). MEASUREMENTS: Frailty, defined as three or more of the following components: unintentional weight loss of more than 10 pounds, weakness (lowest 20% in grip strength), self-reported exhaustion, slow walking speed (lowest 20% in 16-foot walk time in seconds), and low physical activity level (lowest 20% on Physical Activity Scale for the Elderly score). Information about sociodemographic factors, MMSE score, medical conditions (stroke, heart attack, diabetes mellitus, arthritis, cancer, and hypertension), depressive symptoms, and visual impairment was obtained. RESULTS: Of the 1,370 subjects, 684 (49.9%) were not frail, 626 (45.7%) were prefrail (1-2 components), and 60 (4.4%) were frail (>/=3 components) in 1995/96. Using general linear mixed models, it was found that frail subjects had greater cognitive decline over 10 years than not frail subjects (estimate=-0.67, standard error=0.13; P<.001). This association remained statistically significant after controlling for potential confounding factors. CONCLUSION: Frail status in older Mexican Americans with MMSE scores of 21 or higher at baseline is an independent predictor of MMSE score decline over a 10-year period. Future research is needed to establish pathophysiological components that can clarify the relationship between frailty and cognitive decline.
[Mh] Termos MeSH primário: Transtornos Cognitivos/etnologia
Idoso Fragilizado/psicologia
Americanos Mexicanos/psicologia
[Mh] Termos MeSH secundário: Idoso
Altretamine
Transtornos Cognitivos/complicações
Comorbidade
Feminino
Avaliação Geriátrica
Força da Mão
Seres Humanos
Masculino
Entrevista Psiquiátrica Padronizada
Atividade Motora
Força Muscular
Sudoeste dos Estados Unidos
Transtornos da Visão/complicações
Caminhada
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
Q8BIH59O7H (Altretamine)
[Em] Mês de entrada:0812
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080925
[St] Status:MEDLINE
[do] DOI:10.1111/j.1532-5415.2008.01947.x


  5 / 431 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18665286
[Au] Autor:Dornan P; Rowley CN; Priem J; Barry ST; Burchell TJ; Woo TK; Richeson DS
[Ad] Endereço:Centre for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, Ottawa, Ontario, CanadaK1N 6N5.
[Ti] Título:Atom efficient cyclotrimerization of dimethylcyanamide catalyzed by aluminium amide: a combined experimental and theoretical investigation.
[So] Source:Chem Commun (Camb);(31):3645-7, 2008 Aug 21.
[Is] ISSN:1364-548X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A novel method for the cyclotrimerization of dimethylcyanamide to form hexamethylmelamine has been developed using an aluminium amide catalyst; detailed DFT modelling of the catalytic cycle supports a triple insertion, nucleophilic ring closure, deinsertion mechanism.
[Mh] Termos MeSH primário: Alumínio/química
Cianamida/síntese química
[Mh] Termos MeSH secundário: Altretamine/química
Catálise
Cristalografia por Raios X
Cianamida/química
Ciclização
Conformação Molecular
Termodinâmica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
1467-79-4 (dimethylcyanamide); 420-04-2 (Cyanamide); CPD4NFA903 (Aluminum); Q8BIH59O7H (Altretamine)
[Em] Mês de entrada:0909
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080731
[St] Status:MEDLINE
[do] DOI:10.1039/b803732a


  6 / 431 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18591551
[Au] Autor:Green MR
[Ad] Endereço:Network for Medical Communication and Research Analytics, Atlanta, GA, USA.
[Ti] Título:Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancer.
[So] Source:J Clin Oncol;26(19):3112-3, 2008 Jul 01.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma Broncogênico/tratamento farmacológico
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Neoplasias Pulmonares/tratamento farmacológico
[Mh] Termos MeSH secundário: Altretamine/administração & dosagem
Altretamine/efeitos adversos
Altretamine/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Carcinoma Broncogênico/diagnóstico
Carcinoma Broncogênico/mortalidade
Carcinoma Pulmonar de Células não Pequenas/diagnóstico
Carcinoma Pulmonar de Células não Pequenas/mortalidade
Ensaios Clínicos Fase II como Assunto
Ciclofosfamida/administração & dosagem
Ciclofosfamida/efeitos adversos
Ciclofosfamida/uso terapêutico
Feminino
Seres Humanos
Lomustina/administração & dosagem
Lomustina/efeitos adversos
Lomustina/uso terapêutico
Neoplasias Pulmonares/diagnóstico
Neoplasias Pulmonares/mortalidade
Masculino
Metotrexato/administração & dosagem
Metotrexato/efeitos adversos
Metotrexato/uso terapêutico
Projetos de Pesquisa
[Pt] Tipo de publicação:COMMENT; JOURNAL ARTICLE
[Nm] Nome de substância:
7BRF0Z81KG (Lomustine); 8N3DW7272P (Cyclophosphamide); Q8BIH59O7H (Altretamine); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:0808
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080702
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2007.15.7446


  7 / 431 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18305940
[Au] Autor:Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
[Ad] Endereço:University of California San Diego, San Diego, CA 92103, USA. mkelner@ucsd.edu
[Ti] Título:Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
[So] Source:Cancer Chemother Pharmacol;63(1):19-26, 2008 Dec.
[Is] ISSN:1432-0843
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Irofulven (MGI 114, NSC 683863) is a semisynthetic derivative of illudin S, a natural product present in the Omphalotus illudins (Jack O'Lantern) mushroom. This novel agent produces DNA damage, that in contrast to other agents, is predominately ignored by the global genome repair pathway of the nucleotide excision repair (NER)(2) system. The aim of this study was to determine the antitumor activity of irofulven when administered in combination with 44 different DNA damaging agents, whose damage is in general detected and repaired by the genome repair pathway. METHODS: The human lung carcinoma MV522 cell line and its corresponding xenograft model were used to evaluate the activity of irofulven in combination with different DNA damaging agents. RESULTS: Two main classes of DNA damaging agents, platinum-derived agents, and select bifunctional alkylating agents, demonstrated in vivo synergistic or super-additive interaction with irofulven. DNA helicase inhibiting agents also demonstrated synergy in vitro, but an enhanced interaction with irofulven could not be demonstrated in vivo. There was no detectable synergistic activity between irofulven and agents capable of inducing DNA cleavage or intercalating into DNA. CONCLUSION: These results indicate that the antitumor activity of irofulven is enhanced when combined with platinum-derived agents, altretamine, and select alkylating agents such as melphalan or chlorambucil. A common factor between these agents appears to be the production of intrastrand DNA crosslinks. The synergistic interaction between irofulven and other agents may stem from the nucleotide excision repair system being selectively overwhelmed at two distinct points in the pathway, resulting in prolonged stalling of transcription forks, and subsequent initiation of apoptosis.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma/tratamento farmacológico
Dano ao DNA/efeitos dos fármacos
DNA de Neoplasias/efeitos dos fármacos
Neoplasias Pulmonares/tratamento farmacológico
[Mh] Termos MeSH secundário: Altretamine/administração & dosagem
Altretamine/farmacologia
Animais
Antineoplásicos Alquilantes/administração & dosagem
Antineoplásicos Alquilantes/farmacologia
Apoptose/efeitos dos fármacos
Carcinoma/genética
Sinergismo Farmacológico
Feminino
Neoplasias Pulmonares/genética
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Nus
Compostos Organoplatínicos/administração & dosagem
Compostos Organoplatínicos/farmacologia
Distribuição Aleatória
Sesquiterpenos/administração & dosagem
Sesquiterpenos/farmacologia
Transcrição Genética/efeitos dos fármacos
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 0 (DNA, Neoplasm); 0 (Organoplatinum Compounds); 0 (Sesquiterpenes); 6B799IH05A (irofulven); Q8BIH59O7H (Altretamine)
[Em] Mês de entrada:0812
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080229
[St] Status:MEDLINE
[do] DOI:10.1007/s00280-008-0703-0


  8 / 431 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16549840
[Au] Autor:Markman M; Liu PY; Rothenberg ML; Monk BJ; Brady M; Alberts DS
[Ad] Endereço:M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA. mmarkman@mdanderson.org
[Ti] Título:Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
[So] Source:J Clin Oncol;24(9):1454-8, 2006 Mar 20.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if the baseline CA-125 level before initiation of maintenance chemotherapy in women achieving a clinically-defined complete response to primary chemotherapy would be of prognostic value. PATIENTS AND METHODS: Patients included in this retrospective analysis had been treated on one of two previously reported trials of maintenance chemotherapy (three v 12-monthly cycles of paclitaxel; oral altretamine), with a baseline CA-125 level of < or = 35 u/mL. Progression-free survival (PFS) from study entry was analyzed by the Cox regression model. RESULTS: The distribution of premaintenance baseline CA-125 levels for the 384 patients was 58%, 34%, and 8% for values of (A) < or = 10 u/mL, (B) 11 to 20 u/mL, and (C) 21 to 35 u/mL, respectively. The baseline CA-125 was highly statistically significant, either as a categoric variable (P < .001) or as a continuous variable (P < .0001). Median PFS was 24 months, 17 months, and 7 months for groups (A), (B), and (C), respectively. There was no evidence the CA-125 effect differed by trial or treatment in an interaction analysis (P = .70). CONCLUSION: The baseline CA-125 level before initiation of maintenance chemotherapy strongly predicts the risk of subsequent relapse. Patients with premaintenance baseline CA-125 values < or = 10 u/mL have a superior PFS compared with higher levels in the normal CA-125 range.
[Mh] Termos MeSH primário: Antígeno Ca-125/sangue
Recidiva Local de Neoplasia
Neoplasias Ovarianas/patologia
[Mh] Termos MeSH secundário: Idoso
Altretamine/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Progressão da Doença
Feminino
Seres Humanos
Masculino
Meia-Idade
Neoplasias Ovarianas/tratamento farmacológico
Paclitaxel/administração & dosagem
Valor Preditivo dos Testes
Estudos Retrospectivos
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (CA-125 Antigen); P88XT4IS4D (Paclitaxel); Q8BIH59O7H (Altretamine)
[Em] Mês de entrada:0604
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060322
[St] Status:MEDLINE


  9 / 431 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16151309
[Au] Autor:Ninivaggi L
[Ad] Endereço:Department of Medicine, Endocrinology Section, Jersey Shore University Medical Center, Neptune, NJ, USA.
[Ti] Título:Better treatments improve survival of CHD patients.
[So] Source:Nurse Pract;30(9):57-63, 2005 Sep.
[Is] ISSN:0361-1817
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Cardiopatias Congênitas
[Mh] Termos MeSH secundário: Adolescente
Adulto
Assistência ao Convalescente/organização & administração
Altretamine
Criança
Necessidades e Demandas de Serviços de Saúde
Cardiopatias Congênitas/epidemiologia
Cardiopatias Congênitas/terapia
Seres Humanos
Assistência de Longa Duração/organização & administração
Enfermeiras Clínicas/organização & administração
Profissionais de Enfermagem/organização & administração
Papel do Profissional de Enfermagem
Avaliação em Enfermagem
Equipe de Assistência ao Paciente/organização & administração
Educação de Pacientes como Assunto
Prevalência
Apoio Social
Taxa de Sobrevida
Resultado do Tratamento
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
Q8BIH59O7H (Altretamine)
[Em] Mês de entrada:0510
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:050910
[St] Status:MEDLINE


  10 / 431 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:15569973
[Au] Autor:Herzog TJ
[Ad] Endereço:Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA. th2135@columbia.edu
[Ti] Título:Recurrent ovarian cancer: how important is it to treat to disease progression?
[So] Source:Clin Cancer Res;10(22):7439-49, 2004 Nov 15.
[Is] ISSN:1078-0432
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often characterized by administration of multiple, sequential active agents, each of which may or may not be accompanied by a tumor response. Despite the large proportion of patients who relapse and undergo longer-term treatment, the question of optimal treatment duration has not been fully addressed to date. For patients who progress on therapy, the answer is straightforward: they are switched to another active agent, presumably having a different mechanism of action from previous therapies with, ideally, limited overlapping toxicities. However, for patients who remain in partial response or who have stable disease, the answer is less apparent and less clear. The majority of oncologists believe that treatment beyond 6 cycles of a given therapy does not provide any additional benefit to patients. There are some data to support that treatment strategy. However, with the advent of new, less toxic agents, treatment to progression should be further explored. Agents that are potentially well suited for extended treatment intervals may include such properties as absence of cumulative toxicity, non-cross-resistance, positive benefit on quality of life, and convenient schedule. A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients' quality of life, and evidence addressing the potential benefits of longer-term treatment.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Desoxicitidina/análogos & derivados
Neoplasias Ovarianas/tratamento farmacológico
Neoplasias Ovarianas/patologia
Recidiva
[Mh] Termos MeSH secundário: Altretamine/administração & dosagem
Antineoplásicos/uso terapêutico
Carboplatina/administração & dosagem
Cisplatino/administração & dosagem
Desoxicitidina/administração & dosagem
Progressão da Doença
Doxorrubicina/administração & dosagem
Etoposídeo/administração & dosagem
Feminino
Seres Humanos
Paclitaxel/administração & dosagem
Risco
Taxoides/administração & dosagem
Fatores de Tempo
Topotecan/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Taxoids); 0W860991D6 (Deoxycytidine); 15H5577CQD (docetaxel); 6PLQ3CP4P3 (Etoposide); 7M7YKX2N15 (Topotecan); 80168379AG (Doxorubicin); B76N6SBZ8R (gemcitabine); BG3F62OND5 (Carboplatin); P88XT4IS4D (Paclitaxel); Q20Q21Q62J (Cisplatin); Q8BIH59O7H (Altretamine)
[Em] Mês de entrada:0505
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:041201
[St] Status:MEDLINE



página 1 de 44 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde